DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Hauschild A, Agarwala SS, Trefzer U et al
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
J Clin Oncol 2009;
27: 2823-2830
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.